Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Micrologix biotech -- Ignore unavailable to you. Want to Upgrade?

To: Carter Berezay who wrote (748)	2/12/2001 7:22:28 PM
From: DaveAu	Read Replies (1) \| Respond to of 792

Carter, It was on the front page of the National Post. EOM

To: Carter Berezay who wrote (748)	2/15/2001 5:45:37 PM
From: Sean Janzen	Read Replies (4) \| Respond to of 792

Hi Carter, I think this is the story you are discussing. The New England Journal of Medicine Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis nejm.org "In this study, the administration of drotrecogin alfa activated reduced the rate of death from any cause at 28 days in patients with a clinical diagnosis of severe sepsis, resulting in a 19.4 percent reduction in the relative risk of death and an absolute reduction of 6.1 percent. A survival benefit was evident throughout the 28-day study period, whether or not the groups were stratified according to the severity of disease. Our results indicate that in this population, 1 additional life would be saved for every 16 patients treated with drotrecogin alfa activated."